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INTRODUCTION
Rituximab is a chimeric immunoglobulin G1 κ monoclo-
nal antibody that recognizes the CD20 antigen [1]. CD20
antigen is present on the surface of malignant and normal
B-lymphocytes but not on other tissues. This specificity
makes CD20 antigen a suitable target for lymphoma (non-
Hodgkin’s lymphoma [NHL]) treatment. In a multicenter
phase II trial, rituximab was used to treat 37 patients with
low-grade or follicular NHL [2]. The overall response rate
was 50%, and the time to tumor progression for the respon-
ders was approximately 1 year. Rituximab was well tolerated,
with serious side effects occurring in less than 10% of the
patients. A multicenter pivotal trial involving 166 patients
with relapsed low-grade or follicular NHL showed an overall
response rate of 50% (6% complete response [CR] and 44%
partial response [PR]) [3]. Median time to progression for
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ABSTRACT
The major cause of treatment failure following high-dose therapy with autologous hematopoietic cell transplanta-
tion (AHCT) for low-grade lymphomas (non-Hodgkin’s lymphoma [NHL]) is persistent disease or recurrence. Most
patients whose disease progresses following AHCT have resistant disease and limited bone marrow reserve. In this
setting, treatment options are limited and responses to conventional chemotherapy are generally poor. Rituximab is
a chimeric immunoglobulin G1 κ monoclonal antibody that recognizes the CD20 antigen on B-cells. Published data
on the use of rituximab for the treatment of recurrent NHL after autologous transplantation are limited. We pres-
ent a detailed report of anti-CD20 antibody treatment for 8 patients with recurrent follicular low-grade NHL after
high-dose therapy and autologous transplantation. Rituximab was administered at 375 mg/m2 intravenously once
weekly for a total of 4 infusions. Median follow-up for this study was 23.4 months. Six (75%) of 8 patients responded
to rituximab (2 complete response, 4 partial response). The Kaplan-Meier estimated median time to progression
was 17.8 months. Rituximab was generally well tolerated. One patient developed delayed neutropenia. Other side
effects were infusion related and transient. Two patients were re-treated with rituximab for progressive disease and
achieved partial response. In summary, this retrospective study suggests that anti-CD20 antibody treatment is feasi-
ble in the treatment of patients who relapse or progress with low-grade NHL after autologous transplantation.
There appears to be a high proportion of patients who benefit and have durable responses. Anti-CD20 antibody
should be considered as a first-line salvage treatment for patients with CD20+ recurrent low-grade NHL in whom
high-dose therapy has failed.
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responders was 13.2 months. In this trial and in other single-
agent trials, most adverse events were grades 1 and 2 and
occurred mainly during the ﬁrst infusion [3].
Follicular small cleaved and follicular mixed small
cleaved and large cell NHL account for 15% to 30% of
newly diagnosed lymphomas [4]. Most patients with low-
grade lymphomas cannot be cured with conventional
chemotherapy [5,6]. High-dose therapy with autologous
hematopoietic cell transplantation (AHCT) has been inves-
tigated as a treatment modality for low-grade lymphomas
[7-10]. The major cause of failure following transplantation
remains disease progression or recurrence. Most patients
who progress following AHCT have resistant disease and
limited bone marrow reserve. In this setting, treatment
options are limited and responses to conventional chemo-
therapy are generally poor. Second autologous transplanta-
tions have been tried without signiﬁcant beneﬁt [11]. Only
anecdotal accounts of experience with allogeneic hemato-
poietic cell transplantation for recurrent low-grade lym-
phomas following autologous transplantation have been
available [12]. Although selected patients may beneﬁt from
this approach, early mortality remains unacceptably high. 
Published reports of experience using anti-CD20 anti-
body (rituximab) for the treatment of recurrent NHL after
autologous transplantation are very limited. Subset analysis
of the rituximab pivotal trial reveals that 23 patients had
been given rituximab for a recurrence after an autologous
transplantation [3]. Although no specific details were pro-
vided for this subset of patients, response rate in patients
treated with rituximab was higher than that of all other
patients (78% versus 48%). A multicenter phase II study
using anti-CD20 antibody for treatment of patients with
relapsing or refractory aggressive lymphomas included
6 patients with prior history of transplantation [13]. Two of
6 patients responded to rituximab. There is only one report
in the literature addressing the efﬁcacy of anti-CD20 anti-
body therapy for progressive NHL after high-dose therapy
and autologous stem cell transplantation [14]. This retrospec-
tive study involves 7 patients with progressive intermediate-
grade NHL who were treated with rituximab at the time of
relapse after AHCT. Overall response rate was 86%, with 1
patient achieving a CR, 5 achieving PR, and 1 patient hav-
ing stable disease (SD).
To our knowledge, there have been no published reports
specifically addressing the efficacy of anti-CD20 antibody
for treatment of recurrent follicular low-grade lymphomas
after high-dose therapy and AHCT. We present a detailed
report of our ﬁrst 8 patients who underwent high-dose ther-
apy with autologous hematopoietic stem cell transplantation
for follicular low-grade NHL lymphoma and subsequently
received treatment with rituximab for recurrent disease.
PATIENTS AND METHODS
Patient Characteristics
We reviewed the medical records of patients at Wake
Forest University Baptist Medical Center who had low-
grade NHL and were treated between February 1998 and
September 1999 with rituximab for relapsed/progressive
disease following AHCT. Patients with a history of low-
grade NHL that had transformed to a more aggressive his-
tologic subtype were excluded from this analysis. Treatment
with other agents before rituximab for progressive disease
following transplantation was permitted. Patients who were
treated with additional agents during rituximab therapy
were not included. No other speciﬁc exclusion criteria were
used. This retrospective review identiﬁed 8 patients with a
history of either follicular small-cleaved cell or follicular
mixed small-cleaved and large cell NHL. Median age at the
time of rituximab therapy was 56 years (range, 50-67 years).
None of the patients had bulky (>5 cm) disease. Three
patients had splenomegaly (nos. 2, 6, and 8); 1 patient (no.
4) had a prior splenectomy. Only 2 patients (nos. 4 and 7)
had their bone marrow evaluated at the time of rituximab
therapy; 1 of these patients (no. 7) was found to have mini-
mal lymphoma involvement. None of the patients had mor-
phologic evidence of circulating lymphoma cells. Median
number of treatments before transplantation was 3 (range,
2-4). Six patients were treated with 1, 2, or 3 (Table 2) post-
transplantation therapies prior to rituximab; 1 of the 6 (no. 5,
Table 2) underwent a second autologous transplantation for
progressive disease following her initial transplantation. Rit-
uximab was the initial treatment for 2 patients following
posttransplantation relapse. Details of patient characteristics
and prior treatments are given in Tables 1 and 2.
Therapy
Rituximab was administered at 375 mg/m2 intravenously
once weekly for a total of 4 infusions (days 1, 8, 15, and 22)
on an outpatient basis. Premedication with acetaminophen
and diphenhydramine was given to all patients. Some
patients also received cimetidine. The initial infusion rate
for rituximab was 50 mg/hour with subsequent infusion
Table 1. Patient Characteristics
Characteristic
Total, no. (%) 8 (100)
Sex, no. (%)
Male 4 (50)
Female 4 (50)
Stage, no. (%)
III 3 (38)
IV 5 (62)
Histology, no. (%)
Follicular mixed, large and small cleaved 5 (62)
Follicular, small cleaved 3 (38)
B symptoms at diagnosis 2 (25)
Number of pre-BMT treatments, no. (%)
2 2 (25)
3 3 (38)
4 3 (38)
Number of post-BMT treatments, no. (%)
0 2 (25)
1 3 (38)
2 2 (25)
3 1 (12)
Age at diagnosis, median (range), y 47 (42-61)
Age at rituximab, median (range), y 56 (50-67)
Diagnosis to BMT, median (range), mo 40.7 (15.3-170.7)
BMT to Relapse, median (range), mo 20.9 (5.3-59.8)
BMT to Rituximab, median (range), mo 50 (19.6-68.5)
H. Kaya et al.
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rates increased according to package insert instructions if no
toxicity was seen.
Evaluation of Response
Response to rituximab treatment was evaluated with ser-
ial physical examinations, computed tomographic (CT) scans,
and laboratory studies. All patients had comparison CT scans,
which were done shortly before initiation of rituximab treat-
ment. Bone marrow examinations were not routinely done,
but in the 1 patient (no. 7) with documented marrow involve-
ment prior to rituximab, examination of subsequent bone
marrow showed it to be without morphologic evidence of
disease. Complete response (CR) was deﬁned as the disap-
pearance of all evidence of disease and no appearance of new
disease for at least 4 weeks. More than a 50% reduction in the
product of the bidimensional tumor measurements without
appearance of new disease was defined as partial response
(PR). Less than a 50% reduction in tumor size was deﬁned as
SD and was not considered a response. Any evidence of pro-
gression discovered by CT scan and/or physical examination
results was deﬁned as progressive disease (PD).
Statistical Methods
Descriptive statistics (medians and ranges or means and
standard deviations for continuous variables and frequencies
and percentages for categorical variables) were used to sum-
marize the results of this retrospective follow-up study. Out-
comes observed were white blood cell counts, platelet
counts, and hemoglobin levels (calculated as the change in
values from baseline to nadir); adverse effects of treatment;
response to rituximab; and time to progression. Wilcoxon
signed-rank tests were used to assess the signiﬁcance of the
hematologic changes. Kaplan-Meier methods were used to
estimate the time to progression distribution, and methods
described by Korn were used to estimate median follow-up
[15]. Approximate (for continuous variables) and exact (for
binary outcomes) 95% conﬁdence intervals (CIs) were cal-
culated to estimate the possible magnitude of some of the
treatment effects.
RESULTS
Response
CT scans were repeated following the completion of the
last rituximab infusion at a median time of 76 days (range,
21-105 days) and compared with the pretreatment scans for
evaluation of objective responses. Two patients experienced
CR (nos. 1 and 7), 4 had PR (nos. 2, 3, 5, and 6), 1 had SD
(no. 8), and 1 patient had PD (no. 4). Overall, 6 of 8 patients
(75% CI, 24%-91%) responded (CR + PR) to rituximab.
Median follow-up time for this study was 23.4 months.
The Kaplan-Meier estimated median time to disease pro-
gression was 17.8 months (Figure). Two partially responding
patients (nos. 5 and 6) developed PD at 6.4 months and
18.6 months, respectively. The latter patient was re-treated
with 6 weekly infusions of rituximab at the time of progres-
sion and achieved a second PR. Patient no. 8, who had SD,
was re-treated with 6 weekly infusions of rituximab at the
time of progression, approximately 6 months after comple-
tion of the initial rituximab treatment, and achieved a PR.
Only 1 patient (patient no. 4, who initially had PD follow-
ing rituximab) died, at day 172 from complications of subse-
quent chemotherapy. At the time of this report, 4 of 8 patients
were in either PR or CR following therapy with only ritux-
imab. Follow-up for 2 patients (nos. 1 and 7) was approach-
ing 3 years and they continued to be in CR without any
evidence of recurrent/progressive lymphoma. Response to
rituximab for all patients and their status at the time of this
report are summarized in Table 3.
Toxicities
Rituximab was generally well tolerated in this series.
During the first infusion, 1 patient (no. 6) experienced an
Time to disease progression following rituximab treatment.
Table 3. Response to Rituximab and Current Status
Patient Date of Response to Response Retreatment Response to Other Current Follow-up
No. Rituximab, mo/yr Rituximab Duration, mo Date, mo/yr Retreatment Treatments Status Time, mo
1 4/98 CR 30.4+ CR 30.4+ 
2 7/99 PR 17.2+ PD 17.2+ 
3 3/99 PR 22.8+ PR 22.8+ 
4 7/99 PD N/A* 1. Cbl/Dex Died 5.7
2. High-dose Mtx
5 9/99 PR 5.4 PD 15.7+ 
6 3/98 PR 18.6 10/99 PR PR 34.4+ 
7 3/98 CR 34.0+ CR 34.0+ 
8 2/99 SD 6.3 11/99 PR Dex, 9/99 PD 23.4+
*Progressed initially. 
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anaphylactoid reaction, which did not recur during subse-
quent infusions. The same patient also developed delayed
neutropenia 1 month after the last rituximab infusion. She
required hospitalization for neutropenic fevers and promptly
responded to treatment with granulocyte colony-stimulating
factor and intravenous antibiotics. When rechallenged
with rituximab 19 months later, she did not develop neu-
tropenia. Another patient (no. 5) experienced transient
hypotension during the ﬁrst infusion. No other signiﬁcant
side effects were observed. There was no treatment-related
mortality in our patients.
Six of the 8 patients had decreasing white blood cell
counts during therapy, 1 patient had stable counts, and 1 had
increasing counts. The mean ± SD change in white blood
cell count was 1010 ± 1950/µL (95% CI, –340 to 2360). Five
patients experienced decreases in their platelet counts, and
3 had increases. The mean ± SD change in platelets was
18,100 ± 30,600/µL (95% CI, –3100 to 39,300). Four patients
experienced decreases in hemoglobin levels, 1 patient had
stable levels, and 3 had increases in hemoglobin levels. Most
of the changes in the hematologic parameters were not clini-
cally significant, except for development of neutropenia
requiring hospitalization in 1 patient.
DISCUSSION
Most patients with low-grade lymphomas cannot be
cured with conventional chemotherapy. For this group of
patients, high-dose therapy and AHCT appear to provide a
significant progression-free survival benefit compared to
that provided by conventional chemotherapy [16]. The
major cause of treatment failure following transplantation,
however, is disease progression/recurrence. Most patients
who progress following transplantation have resistant dis-
ease and limited bone marrow reserve. Rituximab has been
shown to be an effective agent for the treatment of recur-
rent low-grade lymphomas in the nontransplantation set-
ting. There are few published reports of using this antibody
to treat patients with low-grade lymphomas who have suf-
fered a posttransplantation relapse. We have presented our
initial experience with 8 patients who were treated with rit-
uximab for progressive/recurrent low-grade lymphomas
after high-dose therapy and AHCT.
Our patients were heavily pretreated before transplanta-
tion. Additional chemotherapy treatment following post-
transplantation relapse had failed in most of these patients
before they were considered for rituximab therapy. Six
(75%) of 8 patients responded to rituximab, and most
responses were durable. Two patients were still in complete
remission close to 3 years after rituximab treatment. Our
results are comparable to those reported for previous lim-
ited experience using rituximab for treatment of posttrans-
plantation relapse [3] and appear superior to results of
conventional chemotherapy [17,18]. Half of our patients
(nos. 1, 3, 6, and 7) had a response duration greater with rit-
uximab than they did with transplantation, but the other
4 patients (nos. 2, 4, 5, and 8) did not. Between the 2 groups
of patients there were no apparent differences that would
have enabled us to predict this outcome.
Rituximab was well tolerated in this study. One patient
developed delayed neutropenia, which promptly responded
to growth factor. This patient had a normal white blood cell
count before rituximab treatment was initiated. No speciﬁc
pretreatment factors that might have predisposed this
patient to neutropenia were identified. Her platelet count
and hemoglobin did not decrease after rituximab treatment.
When this patient was re-treated with 6 cycles of rituximab
for progressive disease, no neutropenia was observed. The
incidence of neutropenia in our study was comparable to
that reported in previous articles [2,19]. In our study, other
side effects occurred mainly during the first infusion and
were transient. This report suggests that the toxicity proﬁle
of rituximab does not differ in patients with prior history of
transplantation. This observation is important because most
patients who have undergone high-dose therapy poorly tol-
erate subsequent cytotoxic chemotherapy. Rituximab, with
its favorable toxicity proﬁle, appears to be a feasible option
for this group of patients.
A recent study reported a 40% response rate in patients
re-treated with rituximab, with a longer duration of response
compared to that obtained with their prior course of treat-
ment [20]. Most side effects were mild, and none of the
patients developed human antichimeric antibody. Two of our
patients were re-treated with rituximab for progressive dis-
ease. One patient, who did not respond to the initial 4-week
regimen, achieved a PR 6 months later when he was re-
treated with 6 weekly infusions of rituximab. Another patient,
who had a partial response to the initial 4-week treatment,
achieved a second PR when re-treated with 6 weekly infu-
sions of rituximab. No signiﬁcant side effects were observed
during retreatment with rituximab in these 2 patients.
In conclusion, this retrospective study indicates that
anti-CD20 antibody (rituximab) treatment is feasible in
patients with relapsed/progressive low-grade NHL follow-
ing high-dose therapy and autologous transplantation. High
responses with durability can be achieved. Rituximab is gen-
erally well tolerated by the patients. It is a practical therapy
that can be given on an outpatient basis and completed in a
very short period (22 days). Anti-CD20 antibody (rituximab)
should be considered as a first-line salvage treatment for
patients with recurrent low-grade NHL in whom high-dose
therapy and autologous transplantation have failed.
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